News and Trends 9 Aug 2022 Asthma in the spotlight as Upstream Bio starts trial and UK universities propose new long-term treatment Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, has initiated a phase 1b multiple ascending dose study of UPB-101 in asthma patients with the dosing of the first patient. Meanwhile, a possible way to tackle one of the underlying causes of asthma has been developed by researchers from Aston University and […] August 9, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Relmada Therapeutics gets Fast Track designation for major depressive disorder treatment Relmada Therapeutics, Inc., a late-stage biotech company addressing diseases of the central nervous system (CNS), has been given U.S. Food and Drug Administration (FDA) Fast Track designation to REL-1017, the company’s novel NMDA receptor (NMDAR) channel blocker, as a monotherapy for the treatment of major depressive disorder (MDD). “The receipt of Fast Track Designation represents […] August 9, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Study says gene editing with CRISPR/Cas9 can lead to cell toxicity and genome instability CRISPR/Cas9 is a commonly used gene editing technique. CRISPR allows the introduction of a desired DNA sequence into (virtually) any spot of the genome, thus modifying or inactivating a gene. The technique is widely used in biomedical research and some CRISPR-based therapies are in clinical trials for the treatment of human blood disorders, some types […] August 9, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Pfizer and Valneva to start phase 3 Lyme disease vaccine study Pfizer Inc. and Valneva SE have initiated a phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15. “With increasing global rates of Lyme disease, providing a new option for people to help protect themselves from the disease is […] August 9, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Dallas College gets $8.8M grant to grow biotech workforce in North Texas Dallas College has been awarded a U.S. Economic Development Administration grant to help underserved communities access living-wage jobs in biotechnology. The college noted biotech is a sector poised to grow exponentially with the need for additional highly skilled employees in North Texas, according to the latest labor market intelligence. With approximately $8.8 million in funds […] August 8, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Epigenic Therapeutics raises $20M for gene editing technology Epigenic Therapeutics Co., Ltd., a Chinese biotech gene editing company, has secured $20 million in Series Angel and Pre-A funding. The Series Pre-A funding came from investments by Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund and TigerYeah Capital. Angel investor FountainBridge Capital is also participating. The proceeds will be used to advance the company’s […] August 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Aug 2022Beyond Biotech podcast 8: Biotech Growth Trust, Deep Science Ventures, Endogena Therapeutics, eureKARE This week’s podcast guests are Laura Fletcher, head of business development and strategic partnerships at Deep Science Ventures; Matthias Steger, CEO of Endogena Therapeutics; Rodolphe Besserve, CEO, and Georges Rawadi, chief of biotech studio development, at eureKARE; and Biotech Growth Trust portfolio manager, Geoff Hsu. Endogena Therapeutics to start clinical stage with treatment for blindness […] August 5, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 Immunis closes $10M financing round Immunis Inc., a private U.S. biotech company developing a novel treatment for age and disease-related immune decline, has closed a $10 million series A first closing financing led by Remiges Ventures with participation by several other healthcare investment firms. Proceeds will support clinical assessment of Immunis’ immunomodulatory secretome product in an FDA-awarded phase 1/2a clinical […] August 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 Sanofi and Innovent Biologics to collaborate on oncology medicines and boost China presence Sanofi and Innovent Biologics are to collaborate on providing medicines to patients in China with difficult-to-treat cancers. Innovent is a biopharmaceutical company with clinical development capabilities and a broad commercial footprint in China. Both companies said they are committed to accelerating the development and commercialization of two Sanofi key clinical stage oncology assets: Phase III […] August 4, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 Novavax starts COVID-19 vaccine trial for children aged six months to 11 years U.S. biotech company Novavax, Inc., has started its phase 2b/3 Hummingbird global clinical trial. The trial will evaluate the safety, effectiveness (immunogenicity), and efficacy of two doses of the Novavax COVID-19 vaccine (NVX-CoV2373) in younger children aged six months through 11 years, followed by a booster at six months after the primary vaccination series. “We […] August 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 Gilead Sciences set to acquire MiroBio for $405M California-headquartered Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotech company, have announced the companies have entered into a definitive agreement with Gilead acquiring MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead investigational […] August 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 RoslinCT and Lykan Bioscience combine to create cell therapy CDMO RoslinCT, a cell and gene therapy contract development and manufacturing organization (CDMO) developing life-changing therapies in Edinburgh’s BioQuarter, and Lykan Bioscience, a CDMO focused on cell-based therapies, have entered into a business combination agreement to form a global advanced therapies CDMO. The combined group will offer process development expertise and cGMP manufacturing for a range […] August 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email